The study compares two groups in a random way. In one group, antibiotic treatment is stopped earlier, while in the other group it is continued in the usual way. The child is followed for about 28 days after the start of the fever episode to see how the illness develops and whether any serious infection or other major problem appears. During this time, medical staff monitor symptoms, fever, blood test results, and any side effects or new infections.

The purpose of the study is to find out whether stopping antibiotics earlier is safe in this situation. The trial includes children with cancer and infectious diseases-related fever episodes linked to low white blood cell counts, but it is focused on fever episodes without a confirmed bacterial infection.

Participants in the study will be divided into two groups. One group will receive meropenem through an intravenous infusion, which is a method of delivering medication directly into a vein. The other group will receive a placebo consisting of sodium chloride, a common salt solution. This process is conducted as a double-blind trial, meaning neither the patients nor the medical staff know which substance is being administered during the treatment period.

During the course of the study, medical professionals will monitor how the body responds to the treatment. The focus will be on observing survival rates and checking for organ dysfunction, which refers to a situation where vital organs such as the kidneys, liver, or lungs are not working correctly. The study will also track how long patients remain in the hospital and the overall progress of the illness following the administration of the medication.

The medications being studied include cloxacillin, benzylpenicillin, piperacillin, tazobactam, and vancomycin. These are types of antibiotics, which are medicines used to kill or stop the growth of bacteria. During the study, these drugs will be administered through an intravenous infusion, which is a method where the medicine is delivered directly into a vein through a tube to ensure it enters the bloodstream steadily.

The research involves a method called continuous infusion, meaning the medication is given at a constant rate over a 24-hour period rather than in separate doses. Participants will receive these treatments to help determine the best way to manage bacterial illnesses in a hospital setting.

The purpose of the study is to compare how the body processes these medicines when they are given under the skin compared to when they are given through a vein. During the study, patients will receive either the medicine under the skin or through a vein. Blood samples will be collected to measure the amount of medicine in the blood over time. This helps researchers understand if the medicine reaches the same levels in the body with both methods of giving it. The treatment period will last for up to ten days, and doctors will check how well the infection is responding to the treatment.

The study will also look at whether the medicine levels in the blood stay high enough to fight the infection effectively. Doctors will measure if the signs and symptoms of infection improve or go away without needing additional antibiotics. They will also check if the bacteria causing the infection are eliminated. Any side effects or unwanted reactions that occur during treatment and up to one day after treatment ends will be recorded. This information will help determine if giving these antibiotics under the skin is a safe and effective alternative to giving them through a vein.

The purpose of the study is to assess the presence and level of antibodies, which are proteins in the blood that fight infections, against the circulating influenza virus strains and the vaccine strains of the current season. Participants will receive the vaccine through an injection into the muscle. Blood samples will be taken before and after vaccination to measure the immune response. The study will also look at cellular immunity, which involves the body’s cells responding to the virus, and will measure substances like cytokines, which are proteins that help control the immune response.

The study will take place over several years, with the goal of understanding how well the vaccine works in healthcare workers who are regularly exposed to the flu. This information could help improve future flu vaccines and protect people from getting sick. Participants will be monitored throughout the study to ensure their safety and to gather important data on how their bodies respond to the vaccine.

The purpose of this study is to learn more about how these medications work in the body, as well as to check their safety and how well they are tolerated by the infants. The study will be conducted in two parts, where the infants will receive either a single dose or multiple doses of the medications. The medications will be given through an intravenous infusion, which means they will be delivered directly into the bloodstream through a vein. The study will monitor the infants closely to see how their bodies process the medications and to watch for any side effects or reactions.

Throughout the study, researchers will collect information on how the medications affect the infants’ infections and overall health. This includes checking the levels of the medications in the blood, observing any side effects, and assessing the infants’ recovery from the infections. The study aims to provide valuable information that could help improve the treatment of serious bacterial infections in very young children.

The purpose of the study is to compare the effects of different doses of ciprofloxacin in patients with impaired kidney function to those with normal kidney function. Patients with impaired kidney function will receive a revised, lower dose of ciprofloxacin, either 750 mg taken by mouth once a day or 600 mg given through an intravenous (IV) line once a day. Patients with normal kidney function will receive the regular dose, which is 500 mg taken by mouth twice a day or 400 mg given through an IV line twice a day. The study will look at how much of the drug is present in the body during the first 24 hours of treatment to see if the exposure to the drug is similar between the two groups.

Participants in the study will be monitored to ensure their safety and to gather information on how the drug is processed in their bodies. The study aims to provide valuable insights into the appropriate dosing of ciprofloxacin for patients with different levels of kidney function, which could help improve treatment outcomes for those with bacterial infections.

The treatment being studied includes the use of Norfloxacin, an antibiotic that comes in tablet form. The purpose of the study is to evaluate how likely it is for patients to develop resistance to antibiotics within 28 days of starting treatment. This will be assessed by looking for new bacterial infections or colonizations that are resistant to multiple drugs, known as MDROs (multi-drug resistant organisms).

Participants in the study will receive either the conventional antibiotic treatment or the new strategy based on hospital bacteria monitoring. The study will track various outcomes, such as the development of antibiotic resistance, the resolution of infections, and the overall health and survival of the patients during their hospital stay and up to 28 days after treatment begins. The trial aims to provide insights into the best ways to manage bacterial infections in patients with decompensated cirrhosis, potentially improving treatment strategies and patient outcomes.

The trial involves several medications, including Pivmecillinam hydrochloride, Trimethoprim, Fluconazole, Amoxicillin, Ciprofloxacin, Sulfamethoxazole with Trimethoprim, Amoxicillin with Clavulanic acid, Cefuroxime axetil, Nitrofurantoin, and Linezolid. These medications are being tested to determine their effectiveness in preventing infections after the surgery. Some participants will receive these medications, while others may receive a placebo. The study aims to find the best way to prevent infections and improve recovery after a cystectomy.

Participants in the study will undergo the cystectomy procedure and then be monitored for any signs of infection. The study will track the rate of hospital readmissions due to infections within 90 days after the surgery. It will also look at other factors, such as the timing of stent removal, any complications after surgery, and the overall quality of life of the participants. The study is expected to continue until 2027, with the goal of improving care and outcomes for patients undergoing cystectomy.

The purpose of this study is to determine if the shorter treatment is as effective as the longer one in treating uncomplicated enterococcal bacteremia. Participants in the study will receive either the 7-day or 14-day treatment and will be monitored for their response to the medication. The study will assess various outcomes, such as the success of the treatment, any side effects, and the overall health of the participants during and after the treatment period.

Participants will be closely observed throughout the study to ensure their safety and to gather information on how well the treatments work. The study will help determine if a shorter course of antibiotics can be just as effective, which could lead to shorter hospital stays and reduced exposure to antibiotics. This research is important for improving treatment strategies for patients with uncomplicated bacteremia caused by Enterococcus bacteria.

Infections caused by these resistant bacteria can lead to serious health conditions, such as bacteraemia — a condition where bacteria enter the bloodstream. The study aims to determine if Temocillin is as effective (non-inferior) as Meropenem in treating these infections. The collected data will help assess whether Temocillin could be a viable option for patients.

Participants in the study will receive one of these medications intravenously, meaning they are administered directly into the bloodstream. The treatment will last up to 14 days, with the goal of evaluating overall success, safety, and any complications that might arise during the treatment period. The study also examines aspects such as hospital stay, therapy duration, and the occurrence of any side effects or new infections.

The study will involve children from birth to less than three months old who are hospitalized with suspected or confirmed Gram-negative bacterial infections. These infections can include conditions like complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and bloodstream infections or sepsis. The study will observe how the medication is processed in the body after both a single dose and multiple doses.

Throughout the study, researchers will monitor the children for any side effects and changes in vital signs, which are basic measures of health like heart rate and temperature. They will also conduct physical examinations and laboratory tests to ensure the safety of the participants. The study aims to provide valuable information on the use of cefiderocol in treating these serious infections in very young children.

The purpose of the study is to evaluate the pharmacokinetics (PK) – how the medicine moves through the body – as well as safety and how well it is tolerated. Children will be treated for a short period, with blood samples taken to check drug levels and regular checks of liver and kidney function. After the treatment ends, follow‑up visits will assess whether the infection has cleared and whether any side effects occurred.